Interactions between immunoglobulin G molecules
- PMID: 20600325
- DOI: 10.1016/j.imlet.2010.06.006
Interactions between immunoglobulin G molecules
Abstract
Immune globulin preparations such as intravenous immunoglobulin (IVIG) and monoclonal antibodies are widely used in clinics as effective therapeutic agents for the treatment of a number of autoimmune diseases, cancer, inflammations and other pathologies. Significant amounts of IgG aggregates have been found in the highly concentrated solutions of therapeutic immune proteins. The IgG self-aggregation that appears especially after prolonged storage increases the immunogenicity of the preparations and also modifies their physical properties, first of all producing the high viscosity. The attractive IgG-IgG interactions pose a significant problem for the clinical usage of the immune proteins. During last decades intensive studies of the IgG self-association were performed. The presence of IgG dimers was demonstrated in pooled preparations. These complexes are the result of idiotype-anti-idiotype interactions. In concentrated solutions of immune globulins and monoclonal antibodies self-associated IgG molecules formed a network, increasing the viscosity. The forces responsible for the IgG association are characteristic of the protein-protein interactions in general. The amino acid residues of the Fab and Fc portions participate in the IgG-IgG contacts. Recently contact residues were modified by the site-directed mutagenesis in order to decrease the formation of the IgG self-aggregates. The mutant IgG antibodies were characterized by enhanced stability as compared with the non-modified antibody molecules. Peptic pFc' fragment and the C(H)3 domain were shown to be capable of interacting with Fc regions, thus preventing IgG aggregation. In perspective both approaches could improve the formulation of immune globulin preparations. Removal of IgG aggregates could be achieved by chromatography on hydroxyapatite.
Copyright 2010 Elsevier B.V. All rights reserved.
Similar articles
-
Traces of pFc' in IVIG interact with human IgG Fc domains and counteract aggregation.Eur J Pharm Sci. 2010 Apr 16;40(1):62-8. doi: 10.1016/j.ejps.2010.03.001. Epub 2010 Mar 6. Eur J Pharm Sci. 2010. PMID: 20211252
-
L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions.Biologicals. 2010 Jan;38(1):150-7. doi: 10.1016/j.biologicals.2009.09.002. Biologicals. 2010. PMID: 19931468
-
Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia.Transfusion. 2013 Feb;53(2):261-9. doi: 10.1111/j.1537-2995.2012.03725.x. Epub 2012 Jun 7. Transfusion. 2013. PMID: 22670706
-
Mechanisms of action of intravenous immune globulin in immune-mediated diseases.Clin Exp Immunol. 1996 May;104 Suppl 1:3-9. Clin Exp Immunol. 1996. PMID: 8625540 Review.
-
What is the contents of the magic draft IVIg?Autoimmun Rev. 2008 Jun;7(6):435-9. doi: 10.1016/j.autrev.2008.04.012. Epub 2008 May 2. Autoimmun Rev. 2008. PMID: 18558358 Review.
Cited by
-
Anticomplementary activity of horse IgG and F(ab')2 antivenoms.Am J Trop Med Hyg. 2014 Mar;90(3):574-84. doi: 10.4269/ajtmh.13-0591. Epub 2014 Jan 20. Am J Trop Med Hyg. 2014. PMID: 24445201 Free PMC article.
-
The impact of forced degradation conditions on mAb dimer formation and subsequent influence on aggregation propensity.MAbs. 2022 Jan-Dec;14(1):2127172. doi: 10.1080/19420862.2022.2127172. MAbs. 2022. PMID: 36198003 Free PMC article.
-
Antibody Aggregation: Insights from Sequence and Structure.Antibodies (Basel). 2016 Sep 5;5(3):19. doi: 10.3390/antib5030019. Antibodies (Basel). 2016. PMID: 31558000 Free PMC article. Review.
-
Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.MAbs. 2015;7(4):662-71. doi: 10.1080/19420862.2015.1048411. MAbs. 2015. PMID: 25962087 Free PMC article. Review.
-
Behavior of monoclonal antibodies: relation between the second virial coefficient (B (2)) at low concentrations and aggregation propensity and viscosity at high concentrations.Pharm Res. 2012 Feb;29(2):397-410. doi: 10.1007/s11095-011-0563-x. Epub 2011 Aug 19. Pharm Res. 2012. PMID: 21853361
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous